Close Menu

Ohio State

The researchers plan to add the MSI detection capabilities to an NGS panel and will use the information to guide cancer patients to precision medicine trials.

Croce's Suit

Ohio State's Carlo Croce sues the New York Times over its article on research misconduct allegations, Retraction Watch reports.

This Week in Science

In Science this week: genomic investigation of maize's adaption to temperate climates, and more.

Concerns Issued

Retraction Watch reports that PNAS has issued expressions of concern about two papers from Ohio State's Carlo Croce.

Bit of a Specter

Ohio State University's Carlo Croce is facing new allegations of research misconduct, according to the New York Times.

The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis. 

HudsonAlpha researchers are expected to sequence 20,000 patient tumor and non-tumor samples for ORIEN's Avatar initiative by 2019.

Ohio State's Steve Rissing writes that gene drives may be helpful, but also may be harmful.

With the funding, OSU researchers will conduct cardiovascular phenotyping and exome sequencing of DCM patients of European, African, and Hispanic ancestry.

The database currently includes 60 oncogenes with variants associated with therapies and clinical trials, or that have been functionally characterized.

Pages

Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.

University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.

The Wall Street Journal examines billing codes used by uBiome.

In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.